Presentation at Cowen Healthcare Conference
REDX PHARMA PLC
("Redx" or "the Company" or "Redx Pharma")
Redx Pharma to present at the Cowen 41st Annual Health Care Conference
Alderley Park, 25 February 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, today announces that Lisa Anson, Chief Executive Officer, will give an update on progress made by the Company, at the Cowen 41st Annual Health Care Conference on Thursday 4 March, 2021 at 16:10 GMT / 11:10 EST.
A live webcast of the presentation will be available for viewing at: https://wsw.com/webcast/cowen81/redx.l/2192577
Following the event, a recording will be made available on the investor section of the Company's website at: https://www.redxpharma.com/investor-centre/presentations-analyst-reports-documents-and-videos/ .
|
For further information, please contact: |
|
|
|
|
|
Redx Pharma Plc |
T: +44 1625 469 918 |
|
Iain Ross, Chairman Lisa Anson, Chief Executive Officer James Mead, Chief Financial Officer |
|
|
|
|
|
SPARK Advisory Partners (Nominated Adviser) |
T: +44 203 368 3550 |
|
Matt Davis/Adam Dawes |
|
|
|
|
|
WG Partners LLP (Broker) |
T: +44 20 3705 9330 |
|
Claes Spång/Chris Lee/David Wilson |
|
|
|
|
|
|
|
|
FTI Consulting |
T: +44 20 3727 1000 |
|
Simon Conway/Ciara Martin |
|
About Redx Pharma Plc
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical Proof of Concept. Redx's lead oncology asset, RXC004, is currently in a Phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a Phase 1 clinical study in H1 2021.
The Company's core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 4 hours ago The Renewables Infrastructure Group Limited
- 4 hours ago The Renewables Infrastructure Group Limited
- 4 hours ago Smurfit Westrock (DI)
- 5 hours ago Menhaden Resource Efficiency
- 5 hours ago BP